Sensitivity and Specificity of Xpert MTB/RIF Ultra

Launched by ASSIUT UNIVERSITY · Sep 22, 2023

Keywords

ClinConnect Summary

This clinical trial is researching the effectiveness of two tests, called Xpert Ultra and Xpert MTB/RIF, in diagnosing tuberculosis (TB) and checking for a specific drug resistance (rifampicin resistance) in adults who may have TB, particularly those with forms of the disease that affect areas outside the lungs. The goal is to see how well these tests work in identifying TB in patients from the Assiut population.

To participate in this study, you need to be an adult aged between 18 and 65 years who has gone to the Chest Department with suspected pulmonary (lung) or extrapulmonary (other parts of the body) TB. Unfortunately, if you’ve taken TB medication in the last six months, are under 18, or are in an unstable health condition needing intensive care, you won’t be eligible to join. If you do take part, you can expect to help researchers understand how to better diagnose TB, which could improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Patients presented to Chest Department with suspected pulmonary or extrapulmonary Tuberculosis will be sequentially included
• Exclusion Criteria:
• • Age: less than 18 years. Patients who received anti tuberculous drugs in the past 6 months. Unstable patients or need for ICU admission